Intrexon Corp (NASDAQ:XON) Receives Consensus Rating of “Hold” from Brokerages

Intrexon Corp (NASDAQ:XON) has been assigned a consensus rating of “Hold” from the six brokerages that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $17.00.

A number of analysts have recently issued reports on the company. Bank of America dropped their price target on Intrexon from $7.00 to $6.00 and set an “underperform” rating for the company in a research report on Friday, August 9th. ValuEngine upgraded Intrexon from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. BidaskClub upgraded Intrexon from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Finally, Northland Securities reiterated a “hold” rating and set a $10.00 price target on shares of Intrexon in a research report on Monday, August 12th.

Shares of XON opened at $5.64 on Friday. The company has a market cap of $912.65 million, a PE ratio of -4.12 and a beta of 2.28. The company has a current ratio of 1.92, a quick ratio of 3.20 and a debt-to-equity ratio of 0.97. The stock has a fifty day moving average price of $5.52. Intrexon has a 12-month low of $3.95 and a 12-month high of $10.41.

A number of large investors have recently added to or reduced their stakes in the stock. PFG Advisors lifted its position in Intrexon by 21.7% in the 2nd quarter. PFG Advisors now owns 12,350 shares of the biotechnology company’s stock worth $94,000 after buying an additional 2,200 shares during the last quarter. Cambridge Investment Research Advisors Inc. lifted its position in Intrexon by 4.6% in the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 58,956 shares of the biotechnology company’s stock worth $452,000 after buying an additional 2,600 shares during the last quarter. LPL Financial LLC lifted its position in Intrexon by 15.8% in the 2nd quarter. LPL Financial LLC now owns 19,494 shares of the biotechnology company’s stock worth $149,000 after buying an additional 2,659 shares during the last quarter. Wellington Shields Capital Management LLC lifted its position in Intrexon by 1.7% in the 3rd quarter. Wellington Shields Capital Management LLC now owns 240,800 shares of the biotechnology company’s stock worth $1,377,000 after buying an additional 4,000 shares during the last quarter. Finally, First Republic Investment Management Inc. lifted its position in Intrexon by 13.9% in the 2nd quarter. First Republic Investment Management Inc. now owns 41,000 shares of the biotechnology company’s stock worth $314,000 after buying an additional 5,000 shares during the last quarter. Institutional investors own 76.19% of the company’s stock.

About Intrexon

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.

Recommended Story: Sell-Side Analysts

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.